Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Capucine Baldini

Showing results (61-70 of 101) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 22, 2017
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)Frédéric Bigot, Eduardo Castanon, Capucine Baldini, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicitiesSamia Hajem, Stéphane Ederhy, Stéphane Champiat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2018
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment DiscontinuationMarie-Léa Gauci, Emilie Lanoy, Stéphane Champiat, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2020
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancerPatricia Martin-Romano, Samy Ammari, Yolla El-Dakdoukti, et al.
Cancers|September 9, 2023
Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma PatientsConstance Reichert, Capucine Baldini, Sarah Mezghani, et al.
Cancer Cell|July 1, 2021
Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemicArnaud Bayle, Capucine Baldini, Patricia Martin-Romano, et al.
NEJM Evidence|February 6, 2024
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate CancerKarim Fizazi, Alice Bernard-Tessier, Guilhem Roubaud, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2022
Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trialsPatricia Martin-Romano, Leo Colmet-Daage, Daphne Morel, et al.
European Urology Oncology|May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort EMarinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.
European Journal of Cancer (Oxford, England : 1990)|March 7, 2020
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapiesCapucine Baldini, Patricia Martin Romano, Anne-Laure Voisin, et al.
Pageof 11

Showing results (61-70 of 101) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|August 22, 2017
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)Frédéric Bigot, Eduardo Castanon, Capucine Baldini, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicitiesSamia Hajem, Stéphane Ederhy, Stéphane Champiat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2018
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment DiscontinuationMarie-Léa Gauci, Emilie Lanoy, Stéphane Champiat, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2020
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancerPatricia Martin-Romano, Samy Ammari, Yolla El-Dakdoukti, et al.
Cancers|September 9, 2023
Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma PatientsConstance Reichert, Capucine Baldini, Sarah Mezghani, et al.
Cancer Cell|July 1, 2021
Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemicArnaud Bayle, Capucine Baldini, Patricia Martin-Romano, et al.
NEJM Evidence|February 6, 2024
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate CancerKarim Fizazi, Alice Bernard-Tessier, Guilhem Roubaud, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2022
Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trialsPatricia Martin-Romano, Leo Colmet-Daage, Daphne Morel, et al.
European Urology Oncology|May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort EMarinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.
European Journal of Cancer (Oxford, England : 1990)|March 7, 2020
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapiesCapucine Baldini, Patricia Martin Romano, Anne-Laure Voisin, et al.
Pageof 11